H.C. Wainwright raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $70 from $69 and keeps a Buy rating on the shares following the Q4 report. The firm believes the company’s upcoming clinical data readouts “constitute key value inflection points.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization
- Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Rhythm Pharmaceuticals price target raised to $81 from $75 at Citizens JMP
- Rhythm Pharmaceuticals price target raised to $81 from $80 at Canaccord
- Rhythm Pharmaceuticals: Strong Buy Rating Backed by IMCIVREE’s Growth and Promising Pipeline Developments